Investors Asset Management of Georgia Inc. GA ADV Trims Stake in Eli Lilly and Company (NYSE:LLY)

Investors Asset Management of Georgia Inc. GA ADV reduced its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 3.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,264 shares of the company’s stock after selling 260 shares during the quarter. Eli Lilly and Company comprises approximately 2.4% of Investors Asset Management of Georgia Inc. GA ADV’s holdings, making the stock its 7th largest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Eli Lilly and Company were worth $4,370,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter worth $27,000. Retirement Group LLC raised its stake in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $33,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $35,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $40,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $2.90 during mid-day trading on Monday, hitting $737.26. 2,927,406 shares of the stock traded hands, compared to its average volume of 3,409,004. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59. The business’s 50-day moving average price is $620.02 and its 200 day moving average price is $581.92. The company has a market cap of $699.89 billion, a PE ratio of 127.61, a price-to-earnings-growth ratio of 2.08 and a beta of 0.32. Eli Lilly and Company has a 12-month low of $309.20 and a 12-month high of $745.70.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the firm posted $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is 77.93%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on LLY shares. UBS Group restated a “buy” rating and set a $710.00 target price (up from $612.00) on shares of Eli Lilly and Company in a research note on Friday, October 20th. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Eli Lilly and Company in a report on Thursday, November 9th. They set a “hold” rating and a $535.00 price target on the stock. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $763.00 to $805.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $621.81.

Check Out Our Latest Stock Analysis on Eli Lilly and Company

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the transaction, the insider now owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 195,055 shares of company stock worth $125,254,657 in the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.